Naproxen Could Serve As NSAID Safety Trial Standard, Advisory Panel Says
This article was originally published in The Tan Sheet
Executive Summary
Naproxen should be excluded from any cardiovascular warnings required for NSAIDs, FDA's joint panel on COX-2 safety recommended Feb. 18
You may also be interested in...
Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
The nonselective NSAIDs naproxen and ibuprofen appear neither to increase nor decrease the risk of cardiovascular events, according to a Journal of the American Medical Association data review published online Sept. 12
Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
The nonselective NSAIDs naproxen and ibuprofen appear neither to increase nor decrease the risk of cardiovascular events, according to a Journal of the American Medical Association data review published online Sept. 12
Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
The nonselective NSAIDs naproxen and ibuprofen appear neither to increase nor decrease the risk of cardiovascular events, according to a Journal of the American Medical Association data review published online Sept. 12